Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 4/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10200232 | 1.00 | GABRG2 (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA1 | |
| SCHEMBL16229709 | 0.93 | GABRA1 (0.35) | GABRG2GABRB3GABRA5GABRA6GABRA1 | |
| SCHEMBL12295800 | 0.90 | GABRA5 (0.38) | GABRG2GABRB3GABRA5GABRA6GABRA1 | |
| SCHEMBL12373653 | 0.89 | GABRA1 (0.35) | GABRG2GABRB3GABRA1GABRA2GABRA3 | |
| SCHEMBL10202474 | 0.89 | GABRA1 (0.35) | GABRG2GABRB3GABRA1GABRA2GABRA3 | |
| SCHEMBL12328180 | 0.88 | KRAS (0.33) | KAT2BJAK1 | |
| SCHEMBL13087697 | 0.87 | GABRA1 (0.33) | GABRG2GABRB3GABRA1GABRA2GABRA3 | |
| SCHEMBL6126516 | 0.87 | CDK1 (0.33) | KAT2BJAK1 | |
| SCHEMBL22361269 | 0.87 | CDK1 (0.33) | KAT2BJAK1 | |
| SCHEMBL13087924 | 0.87 | CDK1 (0.33) | KAT2BJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394968-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-12 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GABRG2 3606/4885GABRB3 3509/4885GABRA5 4319/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GABRG2 3280/4885GABRB3 2346/4885GABRA5 3847/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GABRG2 3280/4885GABRB3 2346/4885GABRA5 3847/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | GABRG2 3606/4885GABRB3 3509/4885GABRA5 4319/4885 |
| US-20140205564-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | GABRG2 3280/4885GABRB3 2346/4885GABRA5 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.